Typhoid Fever Vaccines Market to Register a CAGR of 11.9% over the Forecast Period
The Global Typhoid Fever Vaccines Market was valued at USD 225.0 million in 2019, and it is projected to exhibit a CAGR of 11.9% during the forecast period till 2028.
Typhoid, also known as typhoid fever, is a severe illness caused by Salmonella Typhi bacteria that spreads by infected food and water. High fever, fatigue, headache, body pain, vomiting, and diarrhea are common symptoms of typhoid. If not treated on time, typhoid can be fatal. A typhoid vaccine made from inactivated bacteria is recommended for typhoid disease prevention.
If not handled correctly, typhoid can be fatal. Since basic preventive measures such as good hygiene and access to clean water are not accessible in low-income countries, the disease is more prevalent in these regions. However, the spread of the disease in low-income countries can be stopped by putting in place adequate safety and preventive measures. On the other hand, the incidence of the disease is low in developed countries since these countries have proper and adequate sanitation facilities and clean water supplies.
As far as the treatment of typhoid is concerned, antibiotics can be used for this purpose. However, vaccination is more effective in eradicating typhoid since typhoid vaccinations benefit in two ways - one, by protecting those who have been vaccinated, and two, by indirectly providing herd immunity to those who have not been vaccinated when vaccination is done on a large scale.
Several factors are driving the typhoid fever vaccines market, including an increasing government support initiative to combat and curb the occurrence of the disease and immunization campaigns all over the world. A vulnerable aging population and advancements in healthcare are two other important factors contributing to the typhoid fever vaccines market growth. However, a lack of trained experts and qualified practitioners, and the high cost associated with treatment are expected to restrain the growth of the typhoid fever vaccine market to some extent.
Typhoid Fever Vaccines Market, by Vaccine Type
Based on the vaccine type, the market is divided into live attenuated vaccines, capsular polysaccharide vaccines, conjugate vaccines, and others. The capsular polysaccharide vaccines held the largest market share in 2019. The effectiveness of capsular polysaccharide vaccines helps in preventing infections. The increasing number of patients around the world contributes to this segment’s growth. The live attenuated vaccine segment is expected to exhibit the highest CAGR in the global typhoid fever vaccines market during the forecast period.
Typhoid Fever Vaccines Market, by Mode of Administration
Based on the mode of administration, the global market for typhoid fever vaccine has been segmented into oral and parental. In 2019, the parental segment held the largest market share. However, the oral segment is expected to grow at the fastest rate over the forecast period. The increasing contamination of food and water is the main reason that has resulted in the increasing prevalence of typhoid, which in turn, will increase the demand for oral typhoid vaccines.
Typhoid Fever Vaccines Market, by Region
Based on region, the global typhoid fever vaccine market has been segmented as North America, Europe, Asia Pacific, the Middle East & Africa, and South America. Among these regions, North America dominated the typhoid fever vaccines market in 2019. This is largely due to an increasing focus on healthcare and high awareness in patients, leading to an increasing preference for vaccinations for babies, teenagers, and adults. In addition, the easy availability of vaccines in the United States and favorable government policies for vaccination programs have led to market growth in the region.
However, the Asia Pacific market is expected to witness the fastest growth during the forecast period. The impressive growth to be exhibited by this region can be mainly attributed to factors such as increasing initiatives taken by the governments of various countries for immunization and a large population base, especially in countries such as China and India.
Key Developments in the Typhoid Fever Vaccines Market
- In February 2019, Gavi, the Vaccine Alliance, in collaboration with WHO, CDC, and Zimbabwe's Ministry of Health, initiated a campaign to combat the typhoid outbreak in Zimbabwe. The initiative aims to vaccinate 325,000 people with a new typhoid conjugate vaccine in nine suburbs of Zimbabwe's capital (TCV).
Highlights of the Typhoid Fever Vaccines Market Analysis include:
- Forecast and analysis of the typhoid fever vaccine market on a global scale
- Forecast and analysis of the global typhoid fever vaccines market by geography
- Companies in the market and their growth strategies and investment
- A thorough examination of the market and its segments
- An in-depth global industry dynamics and outlook, as well as the factors that are driving and hindering the market
- Recognizing key practices and opportunities that drive market products and distribution
- Profiles of some of the major players in the global typhoid fever vaccines industry, which include GlaxoSmithKline plc, AstraZeneca, Merck & Co. Inc., Sanofi, Pfizer, Inc., and Johnson & Johnson.
By Vaccine Type
- Live Attenuated Vaccine
- Capsular Polysaccharide Vaccines
By Mode of Administration
- North America
- Asia Pacific
- The Middle East and Africa
- South America